1.30

3.17% 0.04

After Hours: 1.30

Vivani Medical Inc (VANI)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vivani Medical Inc stock is traded at $1.30, with a volume of 198.56K. It is up +3.17% in the last 24 hours and up +10.17% over the past month. Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Previous Close:

$1.26

Open:

$1.26

24h Volume:

198.56K

Relative Volume:

0.89

Market Cap:

$112.11M

Revenue:

Net Income/Loss:

$-27.09M

P/E Ratio:

-3.221

EPS:

-0.4036

Net Cash Flow:

$-26.52M

1W Performance:

+7.44%

1M Performance:

+10.17%

6M Performance:

+3.17%

1Y Performance:

+3.17%

1-Day Range:

$1.26

$1.32

1-Week Range:

$1.19

$1.35

52-Week Range:

$0.9228

$1.92

Vivani Medical Inc Stock (VANI) Company Profile

Name

Vivani Medical Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

415-506-8462

Address

1350 S. LOOP ROAD, ALAMEDA

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

VANI's Discussions on Twitter

Compare VANI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VANI Vivani Medical Inc	1.30	106.93M	0	-27.09M	-26.52M	-0.4036
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Vivani Medical Inc Stock (VANI) Latest News

Jul 01, 2026

Price to earnings forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView

Jul 01, 2026

Jun 30, 2026

Vivani Medical Advances SLIM-1 Trial for Obesity Treatment - TipRanks

Jun 30, 2026

Jun 27, 2026

Form 4 Vivani Medical Inc For: 26 June By Investing.com - Investing.com South Africa

Jun 27, 2026

Enterprise value to EBIT forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView

Jun 27, 2026

Jun 26, 2026

Vivani’s Board Overhaul Signals High-Stakes Push into GLP-1 Market - BriefGlance

Jun 26, 2026

Vivani Medical appoints August Moretti to board of directors - Investing.com

Jun 26, 2026

Vivani Medical appoints August Moretti to board of directors By Investing.com - Investing.com UK

Jun 26, 2026

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - GlobeNewswire

Jun 26, 2026

Jun 25, 2026

Price to sales forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView

Jun 25, 2026

Form 4 Vivani Medical Inc For: 25 June By Investing.com - Investing.com Australia

Jun 25, 2026

Price to sales forward of Vivani Medical Inc. – DUS:U5P - TradingView

Jun 25, 2026

Enterprise value to EBITDA forward of Vivani Medical Inc. – DUS:U5P - TradingView

Jun 25, 2026

Price to earnings forward of Vivani Medical Inc. – DUS:U5P - TradingView

Jun 25, 2026

Vivani Medical receives approval to start semaglutide implant trial - Investing.com

Jun 25, 2026

Vivani Medical (VANI) Secures Approval for Phase 1 Clinical Tria - GuruFocus

Jun 25, 2026

Vivani Medical receives approval to start semaglutide implant trial By Investing.com - Investing.com Australia

Jun 25, 2026

Vivani Medical Receives Regulatory Approval to Test Potential Weight Loss Drug Implant - marketscreener.com

Jun 25, 2026

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management - GlobeNewswire

Jun 25, 2026

Jun 24, 2026